{"id":1012,"date":"2021-12-09T10:53:21","date_gmt":"2021-12-09T10:53:21","guid":{"rendered":"https:\/\/forcefieldtx.com\/?page_id=1012"},"modified":"2025-07-08T09:33:05","modified_gmt":"2025-07-08T09:33:05","slug":"about-us","status":"publish","type":"page","link":"https:\/\/forcefieldtx.com\/about-us\/","title":{"rendered":"About Us"},"content":{"rendered":"
[vc_row thb_full_width=”true” thb_row_padding=”true” thb_column_padding=”true” content_placement=”top” parallax=”content-moving” css=”.vc_custom_1741272162039{border-top-width: 15px !important;border-right-width: 15px !important;border-bottom-width: 15px !important;border-left-width: 15px !important;padding-top: 12vh !important;padding-bottom: 10vh !important;background-color: #002350 !important;border-left-style: solid !important;border-right-style: solid !important;border-top-style: solid !important;border-bottom-style: solid !important;border-color: #ffffff !important;}” el_class=”align-center” thb_video_bg=”https:\/\/forcefieldtx.com\/wp-content\/uploads\/2023\/12\/Forcefield_About_2023.mp4″ bg_gradient1=”rgba(0,32,79,0.45)” bg_gradient2=”rgba(0,32,79,0.45)”][vc_column thb_color=”thb-light-column” offset=”vc_col-lg-10″][vc_row_inner][vc_column_inner width=”1\/3″][\/vc_column_inner][vc_column_inner width=”2\/3″][vc_column_text css=”.vc_custom_1639136609201{padding-top: 3vh !important;}” animation=”animation bottom-to-top”]\n

> <\/span>About Us
\n<\/span><\/h4>\n[\/vc_column_text][vc_empty_space height=”3vh”][vc_column_text css=”.vc_custom_1740600269220{padding-right: 25% !important;}” animation=”animation bottom-to-top”]\n

Reason to Believe for the Future.<\/span> <\/span><\/h1>\n[\/vc_column_text][vc_empty_space height=”1vh”][vc_column_text css=”.vc_custom_1708601034013{padding-right: 5vw !important;}” animation=”animation bottom-to-top”]The cardioprotective proteins Forcefield is developing are likely to address other heart disease indications. These proteins have naturally evolved to repair molecular, cellular, and organ damage and consequently have potential in other heart diseases with common aetiology.[\/vc_column_text][vc_empty_space height=”5vh”]\t\n\t\t\t\t\t<\/i><\/span>\t\t\tLearn More<\/span>\n\t\t\t<\/a>\n\t\t[\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row thb_full_width=”true” thb_row_padding=”true” thb_column_padding=”true” content_placement=”top” parallax=”content-moving” css=”.vc_custom_1701809730948{border-right-width: 15px !important;border-left-width: 15px !important;padding-top: 10vh !important;padding-bottom: 15vh !important;border-left-color: #ffffff !important;border-left-style: solid !important;border-right-color: #ffffff !important;border-right-style: solid !important;}” el_class=”align-center” bg_gradient1=”rgba(255,255,255,0.9)” bg_gradient2=”rgba(255,255,255,0.9)” el_id=”INTRO”][vc_column offset=”vc_col-lg-9″][vc_row_inner][vc_column_inner][vc_empty_space height=”2vh”]\t
\n\t\t\t
\n\t\t\t\"Forcefield_icon\"\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t[vc_empty_space height=”2vh”][vc_video link=”https:\/\/vimeo.com\/891387714\/7ba44dbb13″][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_empty_space height=”5vh”][vc_column_text css=”.vc_custom_1639146597732{padding-right: 5vw !important;}” animation=”animation bottom-to-top”]\n
Approach
\n<\/span><\/span><\/h6>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=”1\/2″][vc_column_text animation=”animation bottom-to-top”]\n

Building on successful fusion protein application in other therapy areas these proteins will be developed based on well-established protein science and CMC development approaches.<\/h3>\n[\/vc_column_text][vc_empty_space height=”5vh”][\/vc_column_inner][vc_column_inner width=”1\/2″][vc_column_text animation=”animation bottom-to-top”]Forcefield has a unique and dominant IP position, with a long patent life and exclusivity to the application of these proteins in the treatment of cardiac disease.[\/vc_column_text][vc_column_text animation=”animation bottom-to-top”]While our initial focus is on myocardial infarction (MI), Forcefield has an exclusive licence to the use of these proteins in the treatment of heart diseases, providing the company with multiple opportunities to add value through partnering and potential collaborations.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_empty_space height=”5vh”]\t\n\t\t\t\t\t<\/i><\/span>\t\t\tMeet the Team<\/span>\n\t\t\t<\/a>\n\t\t[\/vc_column_inner][\/vc_row_inner][vc_empty_space height=”5vh”][\/vc_column][\/vc_row][vc_row thb_full_width=”true” thb_row_padding=”true” thb_column_padding=”true” content_placement=”middle” disable_element=”yes” bg_gradient_direction=”-90″ css=”.vc_custom_1701867876372{border-top-width: 15px !important;border-right-width: 15px !important;border-left-width: 15px !important;background-color: #00204f !important;border-left-color: #ffffff !important;border-left-style: solid !important;border-right-color: #ffffff !important;border-right-style: solid !important;border-top-color: #ffffff !important;border-top-style: solid !important;}” bg_gradient1=”rgba(0,32,79,0.4)” bg_gradient2=”rgba(0,32,79,0.4)” el_class=”align-center” el_id=”Quote” thb_video_bg=”https:\/\/forcefieldtx.com\/wp-content\/uploads\/2021\/12\/Forcefield_Treatment_2.mp4″][vc_column thb_color=”thb-light-column” offset=”vc_col-lg-10″][vc_empty_space height=”15vh”][vc_row_inner][vc_column_inner][vc_column_text css=”.vc_custom_1701867774709{padding-right: 5vw !important;}” animation=”animation bottom-to-top”]\n

\u201c<\/span> The incidence of myocardial infarctions is large with 800,000 occurring annually in the US alone and a significant proportion of patients progressing to heart failure, resulting in reduced lifespan and quality of life.<\/h3>\n

Our aim is to revolutionise treatment following acute myocardial infarction and to prevent the cascade of events that may lead to subsequent heart failure. Professor Giacca\u2019s ground-breaking research is the first step in achieving this goal.\u201d<\/span><\/h3>\n

> Dan Gliddon<\/strong><\/span>
\nChief Operating Officer[\/vc_column_text][vc_empty_space height=”5vh”]\t\n\t\t\t\t\t<\/i><\/span>\t\t\tLearn More<\/span>\n\t\t\t<\/a>\n\t\t[\/vc_column_inner][\/vc_row_inner][vc_empty_space height=”15vh”][\/vc_column][\/vc_row][vc_row thb_full_width=”true” thb_row_padding=”true” thb_column_padding=”true” content_placement=”top” parallax=”content-moving” disable_element=”yes” bg_gradient_direction=”0″ css=”.vc_custom_1701794059957{border-top-width: 15px !important;border-right-width: 15px !important;border-left-width: 15px !important;background-color: #ffffff !important;border-left-color: #ffffff !important;border-left-style: solid !important;border-right-color: #ffffff !important;border-right-style: solid !important;border-top-color: #ffffff !important;border-top-style: solid !important;}” el_class=”align-center”][vc_column offset=”vc_col-lg-9″][vc_row_inner el_class=”text-center”][vc_column_inner width=”1\/6″][\/vc_column_inner][vc_column_inner width=”2\/3″]\t

\n\t\t\t
\n\t\t\t\"Forcefield_icon\"\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t[vc_empty_space height=”5vh”][vc_column_text animation=”animation bottom-to-top”]\n

Forcefield plans to meet this call to action as a pioneer of best-in-class therapeutics to preserve and protect heart function.<\/span><\/h3>\n[\/vc_column_text][vc_empty_space height=”5vh”]\t\n\t\t\t\t\t<\/i><\/span>\t\t\tMeet the Team<\/span>\n\t\t\t<\/a>\n\t\t[\/vc_column_inner][vc_column_inner width=”1\/6″][\/vc_column_inner][\/vc_row_inner][vc_empty_space height=”10vh”][\/vc_column][\/vc_row][vc_row thb_full_width=”true” thb_row_padding=”true” thb_column_padding=”true” content_placement=”top” parallax=”content-moving” css=”.vc_custom_1639145149742{border-top-width: 15px !important;border-right-width: 15px !important;border-bottom-width: 15px !important;border-left-width: 15px !important;border-left-color: #ffffff !important;border-left-style: solid !important;border-right-color: #ffffff !important;border-right-style: solid !important;border-top-color: #ffffff !important;border-top-style: solid !important;border-bottom-color: #ffffff !important;border-bottom-style: solid !important;}” el_class=”align-center” el_id=”Team” bg_gradient1=”rgba(232,252,249,0.95)” bg_gradient2=”rgba(232,252,249,0.97)”][vc_column offset=”vc_col-lg-9″][vc_row_inner][vc_column_inner][vc_empty_space height=”8vh”][vc_empty_space height=”3vh”][vc_column_text css=”.vc_custom_1639144327731{padding-right: 5vw !important;}” animation=”animation bottom-to-top”]\n
Leadership Team
\n<\/span><\/span><\/h6>\n[\/vc_column_text][vc_column_text animation=”animation bottom-to-top”]\n

Forcefield\u2019s leadership team has a track record of success in delivering novel discovery biology in cardiovascular disease, biopharmaceutical development and commercialisation, and building successful companies.<\/span><\/h3>\n[\/vc_column_text][vc_column_text animation=”animation bottom-to-top”]Well positioned to move swiftly into the clinic due to the team\u2019s deep and broad expertise in disease biology and development, and backed by a team of industry experts.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_empty_space height=”10vh”][vc_row_inner][vc_column_inner width=”1\/2″ css=”.vc_custom_1639145276046{padding-right: 2vw !important;}”]\t
\n\t\t\t
\n\t\t\t\"Forcefield_John_Tsai\"\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t[vc_empty_space height=”3vh”][vc_column_text animation=”animation bottom-to-top”]\n

John Tsai
\n<\/span><\/h3>\n
Chief Executive Officer
\n<\/span><\/h5>\n[\/vc_column_text][vc_column_text animation=”animation bottom-to-top”]\n

Under the leadership of experienced life sciences executive, John Tsai, MD.<\/h4>\n[\/vc_column_text][vc_column_text animation=”animation bottom-to-top”]With 20 years of leadership experience in life sciences, John manages organisational leadership and strategy as Chief Executive Officer at Forcefield and as an Executive Partner at Syncona Investment Management Ltd.<\/p>\n

He was previously President, Global Drug Development and Chief Medical Officer at Novartis, where he led the Company\u2019s development portfolio across 500 development projects resulting in 20 global drug approvals.<\/p>\n

Before joining Novartis, John was Chief Medical Officer and Senior Vice President of Global Medical Affairs at Amgen and spent 11 years at Bristol-Myers-Squibb, where he held senior leadership positions across both Drug Development and Medical organizations.<\/p>\n

A trained physician, John received his medical degree from the University of Louisville School of Medicine and a Bachelor of Science in Electrical Engineering from Washington University in St. Louis.[\/vc_column_text][vc_icon icon_fontawesome=”fas fa-chevron-down” color=”custom” size=”xs” css=”.vc_custom_1639065920801{margin-left: -2vw !important;}” custom_color=”#65f29b”][vc_empty_space height=”6vh”][\/vc_column_inner][vc_column_inner width=”1\/2″ css=”.vc_custom_1639145270646{padding-right: 2vw !important;}”]\t

\n\t\t\t
\n\t\t\t\"Forcefield_Mauro_Giacca\"\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t[vc_empty_space height=”3vh”][vc_column_text animation=”animation bottom-to-top”]\n

Prof. Mauro Giacca<\/span><\/h3>\n
Scientific Founder<\/span><\/h5>\n[\/vc_column_text][vc_column_text animation=”animation bottom-to-top”]\n

Founded by authority in cardiovascular disease, Professor Mauro Giacca.<\/span><\/h4>\n[\/vc_column_text][vc_column_text animation=”animation bottom-to-top”]Professor of Cardiovascular Sciences and Head of the School of Cardiovascular Medicine & Sciences, King\u2019s College London.<\/p>\n

Fellow of the Academy of Medical Sciences and previously Director-General of the United Nations International Centre for Genetic Engineering and Biotechnology.<\/p>\n

Highly cited researcher with over 370 published papers.[\/vc_column_text][vc_icon icon_fontawesome=”fas fa-chevron-down” color=”custom” size=”xs” css=”.vc_custom_1639065920801{margin-left: -2vw !important;}” custom_color=”#65f29b”][vc_empty_space height=”6vh”][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=”1\/2″]\t

\n\t\t\t
\n\t\t\t\"Forcefield_Dan_Gliddon\"\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t[vc_empty_space height=”3vh”][vc_column_text animation=”animation bottom-to-top”]\n

Dan Gliddon
\n<\/span><\/h3>\n
Chief Operating Officer
\n<\/span><\/h5>\n[\/vc_column_text][vc_column_text animation=”animation bottom-to-top”]\n

Virtual R&D model managed by biologics development specialist Dan Gliddon, COO.<\/span><\/h4>\n[\/vc_column_text][vc_column_text animation=”animation bottom-to-top”]Over 15 years of biopharmaceutical discovery and development experience in pharma, CRO and biotech.<\/p>\n

Former member of exec. leadership team at F-star Therapeutics, leading the clinical translation of their innovative bispecific antibodies, and supporting the company\u2019s corporate development and Nasdaq listing.[\/vc_column_text][vc_icon icon_fontawesome=”fas fa-chevron-down” color=”custom” size=”xs” css=”.vc_custom_1639065920801{margin-left: -2vw !important;}” custom_color=”#65f29b”][vc_empty_space height=”6vh”][\/vc_column_inner][vc_column_inner width=”1\/2″]\t

\n\t\t\t
\n\t\t\t\"Forcefield_Prof_Ajay_Shah\"\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t[vc_empty_space height=”3vh”][vc_column_text animation=”animation bottom-to-top”]\n

Prof. Ajay Shah
\n<\/span><\/h3>\n
Clinical Advisor
\n<\/span><\/h5>\n[\/vc_column_text][vc_column_text animation=”animation bottom-to-top”]\n

Advised by eminent interventional cardiologist, Professor Ajay Shah as Board observer and clinical advisor.<\/span><\/h4>\n[\/vc_column_text][vc_column_text animation=”animation bottom-to-top”]Executive Dean of the Faculty of Life Sciences and Medicine at King\u2019s College London with active research interests in the pathology of heart failure.<\/p>\n

Fellow of numerous cardiology societies and editorial boards of several prestigious journals.[\/vc_column_text][vc_icon icon_fontawesome=”fas fa-chevron-down” color=”custom” size=”xs” css=”.vc_custom_1639065920801{margin-left: -2vw !important;}” custom_color=”#65f29b”][vc_empty_space height=”6vh”][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=”1\/2″]\t

\n\t\t\t
\n\t\t\t\"Elisa_Petris\"\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t[vc_empty_space height=”3vh”][vc_column_text animation=”animation bottom-to-top”]\n

Elisa Petris<\/span><\/h3>\n
Board Director
\n<\/span><\/h5>\n[\/vc_column_text][vc_column_text css=”” animation=”animation bottom-to-top”]\n

Elisa is a Partner of Syncona Investment Management.<\/span><\/h4>\n[\/vc_column_text][vc_column_text animation=”animation bottom-to-top”]She is a Director on the Board of Quell Therapeutics, Beacon Therapeutics and Forcefield Therapeutics and was previously on the Board of former portfolio companies Blue Earth Diagnostics and Neogene, and of current portfolio company Achilles Therapeutics. She was closely involved in the foundation of Quell, Blue Earth, Achilles and Beacon including their operational and strategic set-up.<\/p>\n

Previously, she was a Senior Associate at Michel Dyens & Co. working on transactions covering the healthcare space, and a member of the Life Science team at L.E.K. Consulting based in London. While at L.E.K. she worked on projects for biotech, pharma and private equity clients. Elisa has a PhD in Molecular Biology from Imperial College and an MBA from London Business School.[\/vc_column_text][vc_icon icon_fontawesome=”fas fa-chevron-down” color=”custom” size=”xs” css=”.vc_custom_1639065920801{margin-left: -2vw !important;}” custom_color=”#65f29b”][vc_empty_space height=”6vh”][\/vc_column_inner][vc_column_inner width=”1\/2″]\t

\n\t\t\t
\n\t\t\t\"Nathaniel\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t[vc_empty_space height=”3vh”][vc_column_text css=”” animation=”animation bottom-to-top”]\n

Nathaniel Dahan<\/span><\/h3>\n
Board Director
\n<\/span><\/h5>\n[\/vc_column_text][vc_column_text css=”” animation=”animation bottom-to-top”]\n

Nathaniel Dahan is a Senior Associate of Syncona Investment Management.<\/span><\/h4>\n[\/vc_column_text][vc_column_text css=”” animation=”animation bottom-to-top”]He also works closely with Syncona portfolio company Slingshot Therapeutics, where he is Director of Search & Evaluation.<\/p>\n

Before joining Syncona, Nathaniel was part of the Life Sciences M&A Consulting team at Deloitte, focusing on preparation and execution of large pharma and medtech acquisitions and separations. His background includes strategy execution consulting in pharma, healthcare, and other industries, as well as strategic communications for biotech and medtech start-ups.<\/p>\n

Nathaniel has a PhD in Biomedical Engineering from University College London and was also a postdoctoral researcher at Imperial College London and King’s College London.[\/vc_column_text][vc_icon icon_fontawesome=”fas fa-chevron-down” color=”custom” size=”xs” css=”.vc_custom_1639065920801{margin-left: -2vw !important;}” custom_color=”#65f29b”][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner]\t\n\t\t\t\t\t<\/i><\/span>\t\t\tLearn More<\/span>\n\t\t\t<\/a>\n\t\t[\/vc_column_inner][\/vc_row_inner][vc_empty_space height=”10vh”][\/vc_column][\/vc_row][vc_row thb_full_width=”true” thb_row_padding=”true” thb_column_padding=”true” content_placement=”top” parallax=”content-moving” css=”.vc_custom_1701879851270{border-right-width: 15px !important;border-bottom-width: 15px !important;border-left-width: 15px !important;padding-top: 10vh !important;padding-bottom: 15vh !important;border-left-color: #ffffff !important;border-left-style: solid !important;border-right-color: #ffffff !important;border-right-style: solid !important;border-bottom-color: #ffffff !important;border-bottom-style: solid !important;}” el_class=”align-center” bg_gradient1=”rgba(255,255,255,0.9)” bg_gradient2=”rgba(255,255,255,0.9)” el_id=”Success”][vc_column offset=”vc_col-lg-9″][vc_row_inner][vc_column_inner width=”1\/4″][\/vc_column_inner][vc_column_inner width=”3\/4″][vc_empty_space height=”5vh”][vc_column_text animation=”animation bottom-to-top”]\n

Record of Success<\/span><\/h5>\n[\/vc_column_text][vc_empty_space height=”1vh”][vc_column_text css=”.vc_custom_1639138628803{padding-right: 5vw !important;}” animation=”animation bottom-to-top”]\n

A proven team with a record of success from discovery to commercialisation, backed by leading life sciences investment fund, Syncona.<\/span><\/h2>\n[\/vc_column_text][vc_column_text css=”.vc_custom_1639145561051{padding-right: 5vw !important;}” animation=”animation bottom-to-top”]Forcefield operates a virtual business model that allows efficient use of resources and the flexibility to work with strategic and operational partners sharing our purpose. We welcome enquiries from potential partners with expertise to enhance our research and development efforts and deliver therapeutic benefit to heart attack patients quickly.[\/vc_column_text][vc_column_text css=”.vc_custom_1687256438472{padding-right: 5vw !important;}” animation=”animation bottom-to-top”]\n
Backed by Syncona, a leading healthcare company focused on creating, building and scaling a portfolio of global leaders in life science.<\/h5>\n[\/vc_column_text][vc_empty_space height=”2vh”]\t
\n\t\t\t\n\t\t\t
\n\t\t\t\"Syncona_Logo_Colour_RGB\"\t\t\t\t\t<\/div>\n\t\t\t<\/a>\n\t\t\t\t\t<\/div>\n\t[vc_empty_space height=”5vh”][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row thb_full_width=”true” thb_row_padding=”true” thb_column_padding=”true” css=”.vc_custom_1639064833995{border-right-width: 15px !important;border-left-width: 15px !important;background-color: #ffffff !important;border-left-color: #ffffff !important;border-left-style: solid !important;border-right-color: #ffffff !important;border-right-style: solid !important;}”][vc_column]\t\t